The Study of CM326 in Moderate-to-severe Atopic Dermatitis

Summary

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of CM326 in moderate-severe atopic dermatitis subjects.

Timeline

Start

2022-12-27

Primary completion

2023-12-30

Completion

2024-12-30

Drugs

Indications